Generating AI analysis...
Revenue
$9.47B
++2.28% YoY
EPS (Basic)
$6.03
++10.24% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $9.47B | $9.26B | +2.28% |
Cost of Revenue | $2.67B | $2.72B | -1.95% |
Net Income | $2.67B | $2.49B | +7.52% |
EPS (Basic) | $6.03 | $5.47 | +10.24% |
EPS (Diluted) | $6.02 | $5.47 | +10.05% |
SG&A Expense | $2.38B | $2.32B | +2.59% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $15.47B | $14.24B | +8.64% |
Current Assets | $6.77B | $5.99B | +13.06% |
Total Liabilities | $12.14B | $9.47B | +28.19% |
Current Liabilities | $2.23B | $3.41B | -34.50% |
Stockholders' Equity | $3.33B | $4.77B | -30.17% |
Long-Term Debt | $9.04B | $5.22B | +73.22% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.9B | $2.95B | -1.66% |
Investing Cash Flow | $-748M | $-315M | -137.46% |
Financing Cash Flow | $-1.87B | $-2.66B | +29.70% |
Share Buybacks | $3.23B | $1.86B | +74.11% |
D&A | $487M | $497M | -2.01% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 28.2% | — | — |
ROE | 80.2% | — | — |
ROA | 17.3% | — | — |
Current Ratio | $3.028 | — | — |
Debt to Equity | $3.643 | — | — |
Other companies in Pharmaceuticals